A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3
Clinical trial NCT00002129 · COMPLETED
Trial details
- NCT number
- NCT00002129
- Sponsor
- Otsuka America Pharmaceutical
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.